Perrigo reports $27.5 million net loss for Q3 2026

Item 6. Exhibits

Signatures

58

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS¹

Certain statements in this report are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or our future financial performance² and involve known and unknown risks, uncertainties and other factors that may cause our, or our industry's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by any forward-looking statements. In particular, statements about the proposed divestiture of our Infant Formula business, including the timing and benefits thereof and the anticipated use of proceeds, our expectations, beliefs, plans, objectives, assumptions, future events or future performance contained in this report, including certain statements contained in "Management's Discussion and Analysis of Financial Condition and Results of Operations" are forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "forecast," "predict," "potential" or the negative of those terms or other comparable terminology.

We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control, including: supply chain impacts on our business, including those caused or exacerbated by armed conflict, trade and other economic sanctions and/or disease; general economic, credit, and market conditions; increased or new tariffs by the U.S. or foreign governments (and any retaliatory or reciprocal tariffs) and changes in global trade relations; the impact of the war in Ukraine and any escalation thereof, including the effects of economic and political sanctions imposed by the United States, United Kingdom, European Union, and other countries related thereto; the outbreak or escalation of conflict in other regions where we do business, including the ongoing conflict and social, political and economic environment in Israel and the broader Middle East; current and future impairment charges, if we determine that the carrying amount of specific assets may not be recoverable from the expected future cash flows of such assets; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than we do; pricing pressures from customers and consumers; resolution of uncertain tax positions and any litigation relating thereto, ongoing or future government investigations and regulatory initiatives; uncertainty regarding our ability to obtain and maintain our regulatory approvals; potential costs and reputational impact of product recalls or sales halts; potential adverse changes to U.S. and foreign tax, healthcare and other government policy; the effect of epidemic or pandemic disease; the timing, amount and cost of any share repurchases (or the absence thereof) and/or any refinancing of outstanding debt at or prior to maturity; fluctuations in currency exchange rates and interest rates; receipt of potential earnout payments in connection with the sale of the HRA Rare Diseases Business and the risk that potential costs or liabilities incurred or retained in connection with this transaction may exceed our estimates or adversely affect our business or operations; the satisfaction of certain deferred payment milestones associated with the Dermacosmetics Business divestment; the risk that potential costs or liabilities incurred or retained in connection with the sale of our Rx and other divested businesses may exceed our estimates or adversely affect our business or operations; the ability to consummate the proposed sale of our Infant Formula business on the anticipated terms and timeline, or at all, including the satisfaction or waiver of closing conditions and receipt of required third-party approvals; risks and uncertainties relating to the proposed sale, including potential disruption to our business, relationships with customers, suppliers, employees and other business partners, and risks associated with the separation of the Infant Formula business and related transition arrangements; our ability to realize the anticipated benefits of the proposed sale; the consummation and success of other announced and unannounced acquisitions or dispositions, the satisfaction of deferred payment milestones associated with prior dispositions, and our ability to realize the desired benefits of such transactions; and our ability to execute and achieve the desired benefits of announced cost-reduction efforts and other strategic initiatives and investments, including our ability to achieve the expected benefits from our ongoing restructuring programs and strategic review processes described herein. Adverse results with respect to pending litigation could have a material adverse impact on our operating results, cash flows and liquidity, and could ultimately require the use of corporate assets to pay damages, reducing assets that would otherwise be available for other corporate purposes. These and other important factors, including those discussed in our Form 10-K for the year ended December 31, 2025, in this report under "Risk Factors" and in any subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this re

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED) PERRIGO COMPANY PLC CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in millions, except per share amounts) (unaudited)

Three Months Ended Nine Months Ended

Operating expenses

Loss on extinguishment of debt — — 1.4 —

Earnings (loss) per share

Basic

Diluted

Weighted-average shares outstanding

See accompanying Notes to the Condensed Consolidated Financial Statements.

5

Perrigo Company plc - Item 1

PERRIGO COMPANY PLC CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(in millions) (unaudited)

Three Months Ended Nine Months Ended

See accompanying Notes to the Condensed Consolidated Financial Statements.

6

Perrigo Company plc - Item 1

PERRIGO COMPANY PLC CONDENSED CONSOLIDATED BALANCE SHEETS

(in millions, except per share amounts) (unaudited)

September 26, 2026 December 31, 2025

Assets

Cash and cash equivalents $ 436.6 $ 531.6

Accounts receivable, net of allowance for credit losses of $ 5.2 and $ 6.5 , respectively

Prepaid expenses and other current assets 266.1 231.4

Current assets held for sale — 272.6

Total current assets 2,402.0 2,797.4

Property, plant and equipment, net 825.1 898.7

Operating lease assets 151.4 167.8

Goodwill and indefinite-lived intangible assets 1,696.2 2,054.7

Definite-lived intangible assets, net 2,137.8 2,351.5

Liabilities and Shareholders' Equity

Liabilities

Current liabilities held for sale — 26.8

Total current liabilities 1,020.4 1,012.9

Non-current liabilities

Long-term debt, less current portion 3,282.8 3,603.6

Contingencies - Refer to Note 16

Shareholders' equity

Controlling interests:

Preferred shares, $ 0.0001 par value per share, 10 shares authorized

— —

Ordinary shares, € 0.001 par value per share, 10,000 shares authorized

6,509.0 6,608.2

Accumulated other comprehensive income (loss) ( 39.3 ) 4.8

Total liabilities and shareholders' equity $ 7,484.9 $ 8,535.2

Supplemental Disclosures of Balance Sheet Information

Preferred shares, issued and outstanding

— —

Ordinary shares, issued and outstanding

138.8 137.6

See accompanying Notes to the Condensed Consolidated Financial Statements.

7

Perrigo Company plc - Item 1

PERRIGO COMPANY PLC CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY

(in millions, except per share amounts) (unaudited)

Ordinary Shares

Issued Accumulated

Other

Comprehensive

Income (Loss) Retained

Earnings

(Accumulated Deficit) Total

Shares Amount

Balance at December 31, 2024 136.5 $ 6,733.9 $ ( 162.4 ) $ ( 2,252.1 ) $ 4,319.4

Net loss

Restricted stock plan 1.2 — — — —

Compensation for restricted stock — 11.6 — — 11.6

Cash dividends, $ 0.29 per share

Restricted stock plan 0.6 — — — —

Compensation for restricted stock — 16.8 — — 16.8

Cash dividends, $ 0.29 per share